Topic: Efficacy

Dr. Richard Amerling explains the statistical "trick" of using relative risk instead of absolute risk to inflate the perceived efficacy of pharmaceutical products. He points out that while Pfizer claimed a 95% efficacy rate, the actual absolute risk reduction was only 0.7%, which he deems clinically irrelevant. Amerling traces this practice back to 1980s cholesterol studies and accuses the FDA of a dereliction of duty for not requiring raw source data from manufacturers.

The Informed Consent Action Network (ICANN) has shifted its focus from vaccine safety to investigating vaccine efficacy following a year-long review of thousands of studies. This pivot is driven by reports of mumps outbreaks occurring in 100% vaccinated populations on college campuses and hockey teams. Two Merck whistleblowers have filed a lawsuit alleging the company manipulated mumps vaccine data to maintain its patent monopoly after the FDA questioned the product's declining effectiveness.